Species-specific antibodies of Tetrahymena acid α-glucosidaseBANNO, Y; SASAKI, N; YOSHINO, T et al.Comparative biochemistry and physiology. B. Comparative biochemistry. 1991, Vol 100, Num 1, pp 31-35, issn 0305-0491Article

Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutationsOBA-SHINJO, Sueli M; DA SILVA, Roseli; MUNOZ, Verônica et al.Journal of neurology. 2009, Vol 256, Num 11, pp 1881-1890, issn 0340-5354, 10 p.Article

Pompe Disease: Early Diagnosis and Early Treatment Make a DifferenceCHIEN, Yin-Hsiu; HWU, Wuh-Liang; LEE, Ni-Chung et al.Pediatrics & neonatology (Print). 2013, Vol 54, Num 4, pp 219-227, issn 1875-9572, 9 p.Article

Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe diseaseSUN, B; LI, S; BIRD, A et al.Gene therapy (Basingstoke). 2010, Vol 17, Num 12, pp 1500-1505, issn 0969-7128, 6 p.Article

The Genotype―-Phenotype Correlation in Pompe DiseaseKROOS, Marian; HOOGEVEEN-WESTERVELD, Marianne; VAN DER PLOEG, Ans et al.American journal of medical genetics. Part C, Seminars in medical genetics. 2012, Vol 160, Num 1, pp 59-68, issn 1552-4868, 10 p.Article

Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reductionKYOSEN, S. O; IIZUKA, S; KOBAYASHI, H et al.Gene therapy (Basingstoke). 2010, Vol 17, Num 4, pp 521-530, issn 0969-7128, 10 p.Article

Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease modelJOSEPH, A; MUNROE, K; HOUSMAN, M et al.Clinical and experimental immunology (Print). 2008, Vol 152, Num 1, pp 138-146, issn 0009-9104, 9 p.Article

Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe diseaseTHURBERG, Beth L; MALONEY, Colleen Lynch; VACCARO, Charles et al.Laboratory investigation. 2006, Vol 86, Num 12, pp 1208-1220, issn 0023-6837, 13 p.Article